drugset / Trial / NCT04525014
RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors
NaSingle-groupOpen-labelTreatment
Summary
The PIRATE study tests the experimental drug RRx-001 in combination with 2 chemotherapy drugs that are commonly used in patients with cancer. RRx-001 has been used alone and with other anti-cancer medicines in adults. However, the investigators do not know what effects it will have in children and young adults.
Timeline
- Start
- 2023-01-26
- Primary completion
- 2024-07-29
- Completion
- 2024-07-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NIBROZETONE | Other / unclassified | 0.5 mg/m2 | Intravenous |
| Subject | NIBROZETONE | Other / unclassified | 1 mg/m2 | Intravenous |
| Subject | NIBROZETONE | Other / unclassified | 2 mg/m2 | Intravenous |
| Background | Irinotecan | Small molecule | 90 mg/m2 | Oral |
| Background | Temozolomide | Small molecule | 3 mg/kg | — |
| Background | Temozolomide | Small molecule | 100 mg/m2 | — |